Small by Design. Big on Impact.

Anaheim Bio is unlocking the power of small molecules to transform disease and improve patients' lives.

PRESS RELEASE

Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic

November 5, 2026

People in the US estimated to be affected*

*source: Locust Walk Analysis

4-7%

of adults show signs of CPPD on imaging*

Adult > 60y

0

Approved disease-modifying therapies

THE PROBLEM

A common, painful disease with no therapy that treats its cause.

CPPD is a crystal-induced arthritis: calcium pyrophosphate crystals form in the joint and trigger painful inflammation. It mostly affects adults over 60 and can lead to chronic pain, disability and joint replacement.

OUR PILLARS

A large patient need, a mechanism aimed at the root cause, and a team that knows how to get to the clinic.

High Unmet Need

4–7% of adults have a form of CPPD. We aim to be the first disease-modifying therapy with a measurable biomarker.

Novel Mechanism

PPi drives CPPD crystal formation. Lowering PPi targets the disease at its root cause.

Deep expertise and a track record of moving fast from pre-IND into the clinic.

Experienced Team

OUR APPROACH

Treat the cause, not just the flare.

We're developing the first disease-modifying small molecule for calcium pyrophosphate deposition disease (CPPD), stopping crystal formation at its source.

Pyrophosphate (PPi) is the building block of CPPD crystals. Our lead program, ANA-1, lowers PPi in the joint to limit crystal formation, aiming to be the first disease-modifying therapy for CPPD, with a biomarker we can measure.